- Home
- DB vs ALNY Comparison
DB vs ALNY Comparison
Compare DB & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DB
- ALNY
- Stock Information
- Founded
- DB 1870
- ALNY 2002
- Country
- DB Germany
- ALNY United States
- Employees
- DB N/A
- ALNY N/A
- Industry
- DB Major Banks
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- DB Finance
- ALNY Health Care
- Exchange
- DB Nasdaq
- ALNY Nasdaq
- Market Cap
- DB 33.6B
- ALNY 33.1B
- IPO Year
- DB N/A
- ALNY 2004
- Fundamental
- Price
- DB $17.17
- ALNY $237.92
- Analyst Decision
- DB Buy
- ALNY Buy
- Analyst Count
- DB 2
- ALNY 23
- Target Price
- DB N/A
- ALNY $298.59
- AVG Volume (30 Days)
- DB 1.3M
- ALNY 625.4K
- Earning Date
- DB 01-30-2025
- ALNY 02-13-2025
- Dividend Yield
- DB 2.85%
- ALNY N/A
- EPS Growth
- DB N/A
- ALNY N/A
- EPS
- DB 2.11
- ALNY N/A
- Revenue
- DB $30,817,532,890.00
- ALNY $2,094,795,000.00
- Revenue This Year
- DB N/A
- ALNY $25.14
- Revenue Next Year
- DB $3.26
- ALNY $17.35
- P/E Ratio
- DB $7.90
- ALNY N/A
- Revenue Growth
- DB 1.70
- ALNY 21.54
- 52 Week Low
- DB $12.43
- ALNY $141.98
- 52 Week High
- DB $18.07
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- DB 47.22
- ALNY 34.24
- Support Level
- DB $17.68
- ALNY $241.89
- Resistance Level
- DB $18.05
- ALNY $249.58
- Average True Range (ATR)
- DB 0.24
- ALNY 6.72
- MACD
- DB 0.00
- ALNY -0.37
- Stochastic Oscillator
- DB 30.24
- ALNY 3.07
About DB Deutsche Bank AG
Deutsche Bank is a universal bank operating on a global scale. The bank offers corporate, retail, investment banking, private banking, and asset management to its clients.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.